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Pmel17 is a E100 kDa pigment cell speci¢c glycopro-
tein that plays a crucial part in the morphogenesis of
melanosome precursors. Anti-Pmel17 immunoprecipi-
tates from metabolically pulse labeled melanoma cells
and melanocytes contain, in addition to full-length
Pmel17, a glycoprotein that migrates with a lower rela-
tive molecular weight. Here we show that this glyco-
protein is encoded by an mRNA that results from
alternative splicing of the human Pmel17 gene from
which a cryptic intron is excised. Immunoprecipitation
recapture experiments showed that this glycoprotein
contained both the N- and C-termini of full-length
Pmel17. Sequence analysis of cDNA corresponding to
the alternatively spliced form reveals the loss of three
of 10 imperfect direct repeats from the central region
of the lumenal domain. The product of the splice var-
iant is processed with similar kinetics to full-length
Pmel17, and localizes similarly to late endosomes when
expressed ectopically in nonpigment cells.We speculate
that truncation of the repeat region within Pmel17 alters
either ¢brillogenic activity or the interaction of Pmel17
with melanin intermediates. The expression of an alter-
natively spliced product may furthermore a¡ect the co-
hort of peptides generated for recognition of melanoma
cells by tumor-directed T lymphocytes. Key words:
¢bril formation/gp100/melanoma/melanosome/silver. J Invest
Dermatol 121:821 ^830, 2003
M
elanin biosynthesis and storage are sequestered
within lysosome-related organelles of melano-
cytes and eye pigment epithelia called melano-
somes (Orlow, 1995; Marks and Seabra, 2001). In
order to carry out their unique function, mela-
nosomes harbor a cohort of glycoproteins that are expressed only
in pigment cells. These proteins include enzymes, such as tyrosi-
nase and the tyrosinase-related proteins Tyrp1 and Dopachrome
tautomerase, as well as structural proteins and transporters that
modulate the morphology, intralumenal microenvironment, and
function of the melanosome (Sturm et al, 2001). Melanosome
activity and morphology and the type of melanins produced can
be modulated by the expression or modi¢cation of various com-
ponents through gene regulatory mechanisms or mutation (Hear-
ing, 1999, 2000). This kind of modulation can a¡ect pigmentation
in primary melanocytes or tumorigenicity and/or immunogeni-
city in transformed melanocytes (Kawakami et al, 2000; Over-
wijk and Restifo, 2000; Slinglu¡ et al, 2000).
Pmel17 (also known as gp100 or the product of the Silver locus)
is a type I integral membrane glycoprotein that localizes to the
lumen of melanosome precursors (Kwon et al, 1987; Orlow et al,
1993; Kobayashi et al, 1994; Lee et al, 1996). It is highly expressed
by melanocytes, and serves as a common target for tumor-direc-
ted T lymphocytes in patients with melanoma (Kawakami et al,
1998a).We have shown that Pmel17 aligns with the intralumenal
¢bers that are characteristic of melanosomes and their precursors
(Berson et al, 2001; Raposo et al, 2001), that ectopic expression of
Pmel17 alone is su⁄cient to induce the formation of similar ¢bers
in nonpigment cells (Berson et al, 2001), and that a lumenal do-
main fragment copuri¢es with the ¢bers (Berson et al, 2003).
Others have implicated roles for Pmel17 in immobilizing the
melanin intermediate, DHICA (Chakraborty et al, 1996; Lee et al,
1996), and in detoxifying DHICA and/or other melanin inter-
mediates within the melanocyte (Quevedo et al, 1981; Spanakis
et al, 1992); both of these activities may be associated with the
¢brillogenic activity of Pmel17, resulting in immobilization of
melanin intermediates on ¢brous structures. The hypopigmenta-
tion of silver mice, which harbor a truncated Pmel17 molecule
(Mart|¤ nez-Esparza et al, 1999), indicates that an intact cytoplasmic
domain is required for Pmel17 function.The structural features of
the Pmel17 lumenal domain that e¡ect function within melano-
somes, however, are not known. During its biosynthesis within
melanocytes, Pmel17 undergoes complex processing, involving
cleavage within the lumenal domain, which is required for its
¢brillogenic activity (Berson et al, 2001, 2003), suggesting that its
function may require conformational changes induced by proteo-
lytic processing of this domain. The only other recognizable
features of the lumenal domain are (1) a small region with
homology to polycystic kidney disease (PKD) repeat regions
within the PKD 1 protein (Hughes et al, 1995), and (2) 10 tandem
repeats of a 13 amino acid proline- and glutamate-rich seq-
uence immediately downstream of the PKD repeats (Kwon
et al, 1991).
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Two distinct Pmel17 products resulting from alternative spli-
cing of the mRNA have been described in human melanocytic
cells (Adema et al, 1994; Maresh et al, 1994; Bailin et al, 1996; Kim
et al, 1996). These two forms di¡er by only seven amino acids,
encoded by a 21 bp insertion resulting from use of an alternative
splice acceptor site in exon 10 of the Pmel17 gene, within the jux-
tamembrane region of the lumenal domain (Bailin et al, 1996;
Kim et al, 1996). Here, we describe a second splice variation that
occurs in human melanocytic cells and results in the production
of a smaller Pmel17 product containing a deletion within the lu-
menal domain tandem repeat region.We speculate that expression
of this truncated Pmel17 may alter oligomerization or melanin
binding properties and thereby modulate melanosome structure
and/or function.
MATERIALS AND METHODS
Cell culture and transfection Human melanoma cell lines MNT-1
and 1011-mel were cultured in Dulbecco minimal Eagle’s medium
supplemented with 10% AIM-Vmedium, 20% fetal bovine serum, 1 mM
sodium pyruvate, nonessential amino acids, and antibiotics (penicillin and
streptomycin). Melan-a (Bennett et al, 1989) cells and the mouse T cell
hybridoma, DO11.10 (Roehm et al, 1982) were cultured as described.
Primary melanocytes, a kind gift from Dr M. Herlyn and R. Finko, were
cultured as described (Raposo et al, 2001). HeLa cells were cultured as
described (Calvo et al, 1999), and transfected using FuGene-6 (Roche
Applied Science, Indianapolis, Indiana) according to the manufacturer’s
instructions with 2 mg of total plasmid DNA (0.2 mg of speci¢c plasmid
DNA and 1.8 mg of empty pCI expression vector).
Antibodies aPmel-N and aPmel-I antibodies were raised against
peptides corresponding to N-terminal or internal regions of the Pmel17
lumenal domain. Peptides were synthesized with the following sequences,
representing the indicated residues from full-length Pmel17 with an
additional N-terminal cysteine added for coupling to keyhole limpet
hemocyanin using m-maleimidobenzoyl-N-hydroxysuccinimide ester:
Pmel-N, H2N-(C)TKVPRNQDWLGVSRQLR-CO2H (residues 24^40);
Pmel-I, H2N-(C)QVPTTEVVGTTPGQAPTAE-CO2H (residues 326^
344). Peptide synthesis, coupling, rabbit immunization and production
were performed by Genemed Synthesis (South San Francisco, California).
Anti-peptide antibodies were a⁄nity puri¢ed by passing sodium sulfate
precipitated serum through a column in which peptides were coupled to
SulfoLink gel (Pierce Biotechnology, Rockford, Illinois) according to the
manufacturer’s instructions. Antibodies were eluted with 0.1M glycine pH
2.7, neutralized with Tris base, and dialyzed in phosphate-bu¡ered saline
containing 0.02% sodium azide. Other antibodies and their sources were
as follows: aPEP13h (referred to here as aPmel-C for simpli¢cation), to
Pmel17 cytoplasmic domain (Berson et al, 2001); HMB50 and HMB45,
to Pmel17 lumenal domain (Lab Vision, Fremont, California); and H4A3,
to LAMP1 (Developmental Studies Hybridoma Bank, Iowa City, Iowa).
Chromophore-conjugated secondary antibodies were obtained from
Jackson Immunoresearch (West Grove, Pennsylvania) or from Southern
Biotech (Birmingham, Alabama).
Reverse transcriptase^polymerase chain reaction (reverse transcri-
ptase^PCR) and cloning of alternative splice forms mRNA was
isolated from MNT-1, 1011-mel, HeLa, melan-a, cultured primary human
melanocytes, or D011.10 mouse T cell hybridoma cells using the RNEasy
kit (Qiagen,Valencia, California). For reverse transcriptase reactions, RNA
(15 mg) was incubated with reverse primers, as indicated, heated to 901C,
cooled to 521C for 15 min, and then incubated with Avian Myeloblasto-
sis Virus reverse transcriptase and appropriate bu¡ers according to the
manufacturer’s instructions (Promega, Madison, Wisconsin). Control
reactions lacked reverse transcriptase. After ethanol precipitation, 12.5% of
each reaction was subjected to PCR ampli¢cation with indicated primers
for 30 cycles (1 min at 951C, 1 min at 551C, and 2.5 min at 721C). Parallel
reactions were done using 100 ng of plasmid DNA with Pmel17-l insert.
Reaction products were fractionated by agarose gel electrophoresis
alongside 100 bp markers (Life Technologies, Rockville, Maryland) and
visualized after staining with ethidium bromide. Triads of PCR reactions
with template from reverse transcriptase reactions that contained or lacked
reverse transcriptase enzyme or with plasmid template are shown at
identical exposures for each triad. Primers are indicated inTable I.
For sequencing and subcloning, PCR reaction products using primers
144 and 398 were fractionated by agarose gel electrophoresis, puri¢ed, and
subcloned into pCR2.1 by TA cloning (Invitrogen, Carlsbad, California).
Clones with appropriate sized EcoRI inserts for Pmel17-s and Pmel17-i
were sequenced by automated dideoxy sequence analysis (Children’s
Hospital, Philadelphia, Pennsylvania). To reconstitute a full-length cDNA
for hPmel17-s, the NcoI^XbaI fragment from pCR2.1-hPmel17-s was used
to replace the corresponding fragment in full-length hPmel17-l subcloned
in pSP72 (Promega). Similarly, full-length hPmel17-i was generated by
using the BstXI^XbaI fragment from pCR2.1-hPmel17-i to replace the
corresponding fragment in pSP72-hPmel17-l. From the resultant pSP72
plasmids containing full-length products, EcoRI^XbaI fragments con-
taining the entire reading frame of hPmel17-s or hPmel17-i were
subcloned into the pCI mammalian expression vector (Promega).
Sequences of all inserts were veri¢ed by automated dideoxy sequencing.
Metabolic pulse chase and immunoprecipitation analyses Melanoma
cells, melanocytes, or transfected HeLa cells were metabolically labeled
with 35S-methionine/cysteine as described (Berson et al, 2000) for 20 to 30
min, then chased for 0 to 4 h as indicated. Cell lysates in 1% Triton X-100
were prepared and immunoprecipitated as described (Berson et al, 2000).
For immunoprecipitation/recapture experiments, immunoprecipitated
products were released by addition of 50 mL of 0.5% sodium dodecyl
sulfate (SDS) and heating to 1001C for 5 min. Samples were then brought
to 0.5 mL with lysis bu¡er to dilute the SDS, and subjected to a second
round of immunoprecipitation with indicated antibodies. All immuno-
precipitates were fractionated by SDS^polyacrylamide gel electrophoresis
(SDS^PAGE) and analyzed on a Molecular Dynamics Storm Phosphor
Imaging system using ImageQuant software (Amersham Biosciences,
Piscataway, New Jersey).
Table I. Oligonucleotides used for reverse transcription^PCR
No. Derivation Position in cDNAa Sequence of oligonucleotideb
144 hPmel17 451^474 457GCATCT TCC CTG ATG GTG474
145 hPmel17 855^872 855GGA GAC AGTAGT GGA ACC872
147 hPmel17 1654^1670 1654CAT CGC CAG GGT GCC AG1670
166 hPmel17 1938^1952 GGG CTCACCTGG CAA 1938AGG CGC AGACTTATG1952
171 hPmel17 1454^1492 1454C ACC TTA AGG CTG GTG CAG CAACAA GTC CCC CTG GAT TG1492
172 hPmel17 1492^1454 (R) 1492CA ATC CAG GGG GAC TTGTTG CTG CAC CAG CCT TAA GGT G1454
356 hPmel17 1998^1983 (R) tc ttt tct aga tt1998A GTG ACT GCT GCTATG1983
398 hPmel17 2119^2102 (R) tgt ttt cta ga2119g ttt ctg tca act cca gg2102
232 mGAPDH 47^69 47ATG GTG AAG GTC GGT GTG AAC GG69
233 mGAPDH 1045^1018 (R) 1045CTC CTT GGA GGC CAT GTA GGC CAT CAG G1018
319 hRab5a 57^73 atac cag atc ttg 57ATG GCTAGT CGA GGC GC73
321 hRab5a 704^682 (R) aaga tct aga 704TTA GTTACTACA ACACTG ATT CC682
418 mPmel17 902^921 902GT GGT TCC TCC CCA GTC CCG921
419 mPmel17 1320^1302 (R) 1320CAG GGG AAC TTG TCT CTT C1302
aReverse primers are indicated by (R).
bSuper£uous sequences that are not directly homologous to the cDNA are indicated by italics.
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Western blotting analyses Whole cell lysates of transfected HeLa cells
were treated or not with endoglycosidase H (EndoH, New England
Biolabs, Beverly, MA), fractionated by SDS^PAGE, transferred to
reinforced nitrocellulose membranes, probed with aPmel-N or aPmel-C
antibodies, and developed with alkaline phosphatase-conjugated goat
anti-rabbit immunoglobulin and ECF enhanced chemiluminescence
(Amersham Biosciences) as described previously (Berson et al, 2001).
Immuno£uorescence microscopy analyses Transiently transfected
HeLa cells expressing hPmel17-l, hPmel17-i, or hPmel17-s were ¢xed with
2% formaldehyde in phosphate-bu¡ered saline and stained as described
(Calvo et al, 1999) with antibodies to Pmel17 (HMB50; IgG2a) and to
Lamp1 (H4A3; IgG1), followed by isotype-speci¢c secondary antibodies
conjugated to £uorescein isothiocyanate or Texas Red. Cells were
analyzed on a Leica Microsystems (Bannockburn, Illinois) DM IRBE
microscope, and images were captured, analyzed, and processed for
deconvolution using a Hamamatsu (Hamamatsu, Japan) Orca digital
camera and Improvision (Lexington, Massachusetts) OpenLab software.
Sequence analyses Sequence formatting and comparisons were done
using DNAStar (Madison, Wisconsin) or DNA Strider. The following
GenBank accession nos were used to obtain cDNA sequences for Pmel17
orthologs from the NCBI database: mouse (Mus musculus) Silver, accession
no. NM_021882; chicken (Gallus gallus) MMP115, accession no. D88348;
bovine (Bos taurus) RPE1, accession no. M81193; and horse (Equus caballus)
Pmel17, accession no. AF076780.
RESULTS
Band X is expressed in normal melanocytes in addition
to melanoma cells Anti-Pmel17 immunoprecipitates of cell
lysates from metabolically pulse labeled MNT-1 human
melanoma cells contained, in addition to the E100 kDa band
representing full-length Pmel17, a band with faster migration
(E95 kDa; Berson et al, 2001). This band, referred to as ‘‘band
X’’ was: (1) precipitable with either of two distinct antibodies
to Pmel17 (HMB50, which recognizes the lumenal domain,
and aPmel-C, which binds to the cytoplasmic domain), (2)
susceptible to digestion with EndoH (indicating residence
within a pre-Golgi compartment), and (3) not obvious in lysates
from cells that were chased in the presence of excess unlabeled
methionine (Berson et al, 2001; see also Berson et al, 2003). The
band was distinguished from the proteolytic product, Ma, by
virtue of its slightly distinct migration in gels and by its
susceptibility to digestion with EndoH; Ma, which appears only
after the chase, is resistant to EndoH digestion. Furthermore,
band X was not observed in lysates of transfected HeLa cells
expressing Pmel17 from a transgene (Berson et al, 2001).
To determine whether band X was unique to MNT-1 cells or
represented a coprecipitating product present in untransformed
cells, we subjected cultures of normal primary human
melanocytes to a similar metabolic pulse/chase analysis. As
shown in Fig 1, a similar pattern of immunoprecipitable
products was observed from Triton X-100 cell lysates of these
cells as previously observed in MNT-1 cells. Thus, band X was
present in addition to full-length, core glycosylated ‘‘P1’’ Pmel17
at the pulse. During the chase, both were reduced in intensity and
a slightly faster migrating Ma band appeared concomitantly with
theE28 kDa Mb and the faint, di¡use slower migrating P2 form
representing the Golgi modi¢ed full-length protein (note that
unlike P1 and band X, the migration of Ma and P2 varies
among melanoma cells and primary melanocytes most likely
due to di¡erential terminal glycosylation; Vogel and Esclamado,
1988; Chiamenti et al, 1996). Although reduced in intensity, P1
persists throughout the chase in all cells, likely due to ine⁄cient
exit from the endoplasmic reticulum (Vogel and Esclamado, 1988;
Adema et al, 1994; Kobayashi et al, 1994; Berson et al, 2001, 2003).
All bands were precipitable with both HMB50 and aPmel-C,
indicating that lumenal and cytoplasmic domains were both
present (and linked in the case of Ma/Mb). Similar results were
obtained in a second primary human melanocyte culture and in
1011-mel human melanoma cells. By contrast, only one band
corresponding to the full-length product was observed in
immunoprecipitates of pulse-labeled mouse melanocytic cell
lines melan-a and melan-a3 (unpublished data). Thus, band X
represents a coprecipitating product present in normal and trans-
formed human melanocytes but absent in mouse melanocytes.
Band X contains the N- and C-termini of Pmel17 To
determine whether band X represented a modi¢ed form of
Pmel17 or a coprecipitating product, we subjected radio-labeled
cell lysates to a two-step immunoprecipitation recapture
protocol using anti-Pmel17 antibodies. Pmel17 was ¢rst immuno-
precipitated using aPmel-C or HMB50 under nondenaturing
conditions from Triton X-100 lysates of 35S-methionine pulse-
labeled MNT-1 cells (Fig 2a, lanes 1 and 2) or cells chased for 2 h
in the absence of 35S-methionine (Fig 2b, lanes 12 and 13). Material
from these primary immunoprecipitates was then eluted by
boiling in the presence of SDS and a reducing agent; this
treatment not only dissociates material from the antibodies,
but also disrupts any potential complexes containing Pmel17
associated noncovalently or via disul¢de bonds to other
polypeptides. After removal of the beads, the SDS was diluted
and eluates were subjected to a second round of immuno-
precipitation using rabbit antibodies directed against peptides
corresponding to the N- or C-terminus of Pmel17; because of
the SDS treatment, only polypeptides directly recognized by
these antibodies should be immunoprecipitated in the second
step. As shown in Fig 2(a, lanes 3, 4, 6, and 7), band X is present
in the second step immunoprecipitates using both anti-Pmel17
antibodies from lysates of pulse-labeled cells; it was also
precipitable using the aPmel-I antibody to an intralumenal
peptide (unpublished data). As a control, using lysates from cells
chased for 2 h in the absence of radiolabel, Ma or Mb were
precipitable only with the N- or C-terminus-directed antibody,
Figure1. Processing of Pmel17 and appearance of band X in un-
transformed human melanocytes. Primary human foreskin-derived
melanocytes were pulse labeled with 35S-methinonine/cysteine for 30 min
and then chased for 0, 1, or 4 h in the presence of excess unlabeled methio-
nine and cysteine. Triton X-100 cell lysates (C) or culture supernatants (S)
were immunoprecipitated with antibodies to the lumenal (HMB50, lanes
1^5) or cytoplasmic (aPmel-C, lanes 6^10) domains of Pmel17, and immu-
noprecipitates were analyzed by SDS^PAGE and phosphorimaging. The
position of molecular weight markers is indicated in the middle. The posi-
tions of the core glycosylated precursor (P1), band X (X), the Golgi-pro-
cessed P2 form, and the proteolytic products Ma and Mb are indicated.
Arrows, nonreproducible bands that most likely re£ect post-lysis degrada-
tion products.
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respectively (Fig 2b, lanes 14, 15, 17, and 18). No bands were
recaptured using nonspeci¢c antibodies in the second step (lanes
5, 8, 16, and 19) or antibodies to an irrelevant protein in the ¢rst
step (lanes 9^11 and 20^22). From these data, we conclude that
band X corresponds to a variant form of Pmel17 and that it
contains both the N- and C-termini. We therefore refer to this
product herein as Pmel17-s for short form. The data also indicate
that Pmel17-s is distinct from the processed Ma cleavage product
of Pmel17 (although Ma likely includes a product derived from
Pmel17-s; see below).
Identi¢cation of an alternatively spliced, truncated form of
Pmel17 The presence of both the N- and C-termini within
the single Pmel17-s polypeptide indicates that Pmel17-s cannot
be a proteolytic digestion product of full-length Pmel17.
Furthermore, the fact that Pmel17-s and full-length Pmel17
continue to migrate di¡erently following digestion with EndoH
(Berson et al, 2001) excludes the possibility that the two products
di¡er only by the degree of N-linked glycosylation.We therefore
hypothesized that Pmel17-s was an alternative Pmel17 translation
product derived from a truncated Pmel17 mRNA.
To test for the existence of such an mRNA species, we
performed reverse transcriptase^PCR analyses of MNT-1
mRNA using primer sets corresponding to various portions of
the Pmel17 coding region (see Table I, Fig 3a). As expected, a
single band of E182 bp was detected using a primer set
spanning the coding region for the cytoplasmic domain (Fig 3b,
lanes 13^15). Using primer sets that spanned only the 30 third of
the Pmel17 coding region, two reverse transcriptase^PCR
products could be observed di¡ering by only approximately 20
bp (Fig 3b, lanes 7^12). These products were not observed
from reverse transcriptase^PCR reactions using mRNA from
nonmelanocytic cells (see Fig 4) or from preparations of MNT-
1mRNA in which the reverse transcriptase enzyme had not been
included (Fig 3b, lanes 8, 11, and 14), illustrating the speci¢city of
the signal. These products likely represent the ampli¢ed products
of the two previously described alternatively spliced mRNA: a
less abundant long form, originally cloned and described as
Pmel17 (Kwon et al, 1991), and a more abundant form, originally
cloned and described as gp100 or ME20, lacking 21 bp encoding
seven amino acids (Adema et al, 1994; Maresh et al, 1994) (see
Fig 5c).We refer to these two products as Pmel17-l and Pmel17-i
for long and intermediate forms, respectively. Even though
our reverse transcriptase^PCR reactions were not performed
quantitatively, the relative abundance of these forms among
our reverse transcriptase^PCR products from MNT-1 mRNA
mirrors that previously described in other melanocytic cells in
which Pmel17-i is approximately 5-fold more abundant than
Pmel17-l (Bailin et al, 1996; Fig 3b, lanes 7^12). The di¡erence
in predicted molecular mass of Pmel17-l and Pmel17-i is less
than 700 Da, and is unlikely to be responsible for the E5000
Da di¡erence between the unprocessed full-length Pmel17 (P1
form) and Pmel17-s observed in immunoprecipitates. Thus, the
di¡erence between Pmel17-s and the longer forms is unlikely
due to splice di¡erences in the 30 half of the Pmel17 coding
region.
By contrast, when reverse transcriptase^PCR reactions were
performed using primer sets that spanned a longer region
encompassing more 50 coding regions of full-length Pmel17, two
bands di¡ering byE 130 bp were observed (Fig 3b, lanes 1^6; due
to the large size of these products, the 21 bp di¡erence between
Pmel17-l and Pmel17-i would not be expected to be resolved).
The smaller of these products was less abundant than the larger,
representing on average approximately 10% of the total signal. Its
size and abundance is consistent with the potential that this band
was derived from the mRNA encoding Pmel17-s. Consistently,
Figure 2. Immunoprecipitation/recapture of band X using anti-Pmel17 antibodies.MNT-1 cells were pulse labeled with 35S-methinonine/cysteine
for 30 min and then chased for 0 (a) or 2 h (b) with excess unlabeled methionine and cysteine. Triton X-100 cell lysates were immunoprecipitated using the
anti-Pmel17 antibodies aPmel-N (lanes 1 and 12), aPmel-C (lanes 2^5 and 13^16), or HMB50 (lanes 6^8 and 17^19), or the anti-Tyrp1 antibodyTA99 (lanes 9^11
and 20^22). Material from the ¢rst immunoprecipitate was eluted by boiling with SDS and reducing agent, cooled, diluted with Triton X-100 lysis bu¡er,
and subject to a second round of immunoprecipitation using normal rabbit serum (NRS; lanes 5, 8, 11, 16, 19, and 22) or the anti-Pmel17 antibodies aPmel-C
(lanes 3, 6, 9, 14, 17, and 20) or aPmel-N (lanes 4, 7, 10, 15, 18, and 21). Material from the ¢rst round (lanes 1, 2, 12, and 13) or second round (all other lanes) of
immunoprecipitation were fractionated by SDS^PAGE and analyzed by phosphorimaging. The position of molecular weight markers is indicated to the
right of each gel, and the migration of the P1, P2, Ma, Mb, and band X forms of Pmel17 are indicated. Note that (b) was exposed for a longer period of
time than (a) in order to emphasize the Ma and Mb bands.
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the same doublet was observed in reverse transcriptase^PCR
products from two primary melanocyte cultures and an
additional melanoma cell line, whereas neither product was
observed from reverse transcriptase^PCR reactions using RNA
from nonmelanocytic HeLa cells or from reactions using
melanocytic cell mRNA but lacking reverse transcriptase
enzyme (Fig 4). Furthermore, reverse transcriptase^PCR
reactions using comparable primers for mouse Pmel17 and
Figure 3. Detection of Pmel17 mRNAwith an internal deletion by reverse transcriptase^PCR of mRNA from MNT-1 cells. (a) Schematic
diagram of Pmel17 cDNA and position of primers used in this analysis. The noncoding 50 - and 30 -untranslated regions (50 UT and 30 UT) are indicated
as solid lines, and the coding region is boxed and divided according to the domain structure of the encoded protein. Indicated are the regions encoding the
signal peptide; the lumenal domain PKD homology domain, tandem repeat domain, cleavage site separating the Ma and Mb fragment (CS), and the
peptide excised in Pmel17-i; and the transmembrane (TM) and cytoplasmic (Cyt.) domains. The length of our Pmel17-l cDNA is indicated by nucleotide
positions 1 and 2177. Bottom, the position of the primers, noted inTable I, within the cDNA is indicated, with arrows showing the direction of the primer.
Not shown is primer 172, which is the reverse complement of 171. (b) Reverse transcriptase^PCR reactions from MNT-1 mRNA. MNT-1 mRNAwas
reverse transcribed using primer no. 398 (lanes 1, 4, 10, and 13) or no. 356 (lane 7); a parallel sample was incubated under identical conditions in the absence of
reverse transcriptase enzyme (lanes 2, 5, 8, 11, and 14). Reaction products or 100 ng of puri¢ed Pmel17-l plasmid (lanes 3, 6, 9, 12, and 15) were subject to 30 cycles
of PCR using the indicated forward primers and either no. 356 (lanes 7^9) or no. 398 (all other lanes) as the reverse primer. M, 100 bp markers; arrowhead
indicates the 600 bp marker band. Predicted sizes for each of the reaction products for Pmel17-l are 1669, 1265, 524, 444, and 182 bp, respectively.
Figure 4. Broad expression of small Pmel17 mRNA in melanocytic cells by reverse transcriptase^PCR.mRNA isolated from the melanoma cell
lines MNT-1 (lanes 1^3 and 16^18) or 1011-mel (lanes 4^6), from two di¡erent primary foreskin melanocyte cultures (11 FSM-1, lanes 7^9; 11 FSM-2, lanes
10^12), or from nonmelanocytic HeLa cells (lanes 13^15 and 19^21) was reverse transcribed using primer no. 172; parallel reactions were performed identically
but with no added reverse transcriptase enzyme (lanes 2, 5, 8, 11, 14, 17, and 20).The products of these reactions or 100 ng of plasmid encoding Pmel17-l (lanes 3,
6, 9, 12, and 15) were subjected to 30 cycles of PCRusing primers no. 172 and no. 145 to amplify a region that would best distinguish the short and long forms
of Pmel17 (lanes 1^15). The 638 bp reaction product, predicted from the sequence of Pmel17-l, is indicated by a line, and the 510 bp reaction product corre-
sponding to the short form is indicated by an arrow. As a positive control, a 650 bp cDNA fragment for Rab5a was ampli¢ed using primers no. 319 and no.
321 from RNA isolated from MNT-1 (lanes 16 and 17) and HeLa cells (lanes 19 and 20); the same reaction was also performed on Pmel17-l plasmid (lanes 18
and 21).
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mRNA from the mouse melanocytic cell line, melan-a, yielded
only a single band corresponding to the expected size of full-
length mouse Pmel17 (data not shown), consistent with the
failure to detect a Pmel17-s isoform by immunoprecipitation in
these cells.
In order to de¢ne better the nature of this alternative form of
Pmel17, products from reverse transcriptase^PCR reactions
from MNT-1 cells were fractionated, excised, subcloned into
plasmid vectors, and sequenced. Concordant results from three
independent clones derived from two separate reverse
transcriptase^PCR reactions using di¡erent primer sets revealed
that the smaller product lacked 126 bp derived from the middle
of the Pmel17 mRNA (nucleotides 1118^1243 of the coding
region; Fig 5a). This sequence, encoding more than three of the
direct repeats within the Pmel17 lumenal domain (Fig 5b), is
encompassed within exon 6 of the Pmel17 gene. The deleted
region begins with a ‘‘gt’’ dinucleotide and ends with an ‘‘ag’’
dinucleotide (Fig 5a) but lacks other consensus sites for intron
recognition, suggesting that it may represent an infrequently
excised, cryptic intron within exon 6. The polypeptide region
predicted by the translation of this region (Fig 5a, bold type)
would have a mass of 4235 Da, consistent with the reduction in
relative molecular mass by SDS^PAGE of Pmel17-s compared
with full-length Pmel17 (Figs 1 and 2). Among the isolated
cDNA clones that lacked this 126 bp region, some contained and
others lacked the 21 bp region that distinguishes Pmel17-l from
Pmel17-i; thus, the two alternative splicing reactions can occur
independently and can result in four di¡erent Pmel17 mRNA
products (Fig 5c).
Pmel17-s is processed and localized similarly to full-length
Pmel17 To con¢rm that the truncated mRNA encodes
Pmel17-s and to compare its biosynthetic characteristics with
that of other Pmel17 isoforms, we constructed mammalian
expression vectors encoding full-length Pmel17-s, Pmel17-i, and
Pmel17-l and expressed the encoded products by transfection in non-
melanocytic HeLa cells. As shown in Fig 6(a), the product of the
putative Pmel17-s cDNA immunoprecipitated from cell lysates
of metabolically pulse-labeled, transfected HeLa cells (lane 5)
comigrated with Pmel17-s from immunoprecipitates of MNT-1
Figure 5. Sequence analysis of cDNA corresponding to the small Pmel17 mRNA reveals a deletion of part of the internal repeats. (a) Com-
parison of the sequence of the small and large Pmel17 mRNA. Shown at top is a schematic of the Pmel17-l cDNA (see Fig 3a for explanation). The
indicated region of Pmel17-l and Pmel17-i is expanded below to show the nucleotide and predicted amino acid sequence. The region in bold type is absent
from the cDNA isolated for the short form; the nucleotide and predicted amino acid sequence of this region of the short form is indicated at the bottom.
Numbers correspond to the nucleotide position of our Pmel17-l cDNA clone and the amino acid positions of the mature protein (with signal peptide
removed). (b) Comparison of the direct repeat region in Pmel17-l/PMEL17-i with that predicted from the nucleotide sequence of Pmel17-s. The alternative
splice removes 3.5 of the 10 imperfect direct repeats. Numbers correspond to the amino acid positions of the mature protein (with signal peptide removed).
(c) Schematic diagram of four Pmel17 mRNA for which the cDNAwere isolated from MNT-1 cells. Lumenal, transmembrane (tm) and cytoplasmic (cyto)
domains are indicated. Spliced regions are indicated by gray shading.
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cells (lane 4). By contrast, Pmel17-l and Pmel17-i from lysates of
pulse-labeled transfected HeLa cells both comigrated with the P1
form observed in MNT-1 cells (compare lanes 1 and 3 with lane 2).
Taken together with the data shown in Fig 2, this con¢rms that
Pmel17-s is the product of the alternatively spliced, truncated
Pmel17 mRNA.
Pmel17 is cleaved in a post-Golgi compartment to Ma and Mb
fragments (Berson et al, 2001). To determine whether the internal
deletion within Pmel17-s a¡ected the processing of Pmel17 to
these fragments, we analyzed transfected HeLa cells by western
blotting using antibodies that detect either fragment; whole cell
lysates were untreated or treated with EndoH to distinguish core-
glycosylated, EndoH-sensitive, pre-Golgi localized isoforms
from fully processed, EndoH-resistant, post-Golgi forms. Using
aPmel-C to the cytoplasmic domain, a mostly EndoH-resistant
Mb band, in addition to the full-length EndoH-sensitive P1
precursor, was found to accumulate in cells transfected with all
three Pmel17 isoforms (Fig 6b, top panel; in data not shown, the
migration of EndoH-treated P1 was similar to that of P1 treated
with protein N-glycanase F, indicating that all N-linked glycans
were susceptible to EndoH digestion). Consistent with previous
results (Kobayashi et al, 1994; Berson et al, 2001), the transient P2
form does not accumulate, whereas the slow exit of Pmel17 from
the endoplasmic reticulum is responsible for the accumulation of
P1.Whereas the P1 band for Pmel17-s di¡ered in migration from
that for Pmel17-l and Pmel17-i, the Mb band from each migrated
identically, consistent with the splice variation occurring with-
in the Ma coding region. Using the aPmel-N antibody to
the lumenal domain, a stable EndoH-resistant Ma fragment was
found to accumulate in cells expressing each of the three isoforms
(note the collapse of EndoH-digested P1 into comigrating
EndoH-resistant Ma; Fig 6b, bottom panel). As expected, the
Pmel17-s-derived Ma fragment migrated faster than the Pmel17-
l- and Pmel17-i-derived Ma fragment. Metabolic pulse/chase and
immunoprecipitation analyses also showed similar processing
patterns for all three Pmel17 isoforms (data not shown). Thus,
alternative splicing does not appear to a¡ect the biosynthetic
processing of Pmel17.
When expressed ectopically in nonpigment cells, Pmel17-l
localizes to the intralumenal vesicles of late endosomal
multivesicular structures and to ¢bers that form de novo upon
Pmel17-l expression (Berson et al, 2001). To determine whether
alternative splicing a¡ects localization, transfected HeLa cells
were analyzed by immuno£uorescence microscopy for the
localization of each of the Pmel17 isoforms. As shown in Fig 7,
all three isoforms display a similar steady-state localization to
vesicular compartments throughout the cytoplasm, as was
shown for Pmel17-l. In all three cases, these vesicles overlapped
with a subset of Lamp1-containing compartments, and thus
correspond to late endosomes or lysosomes; in cells with very
high expression, these Lamp1-positive structures were enlarged,
and the Lamp1 staining could be observed surrounding the
Pmel17 staining (Fig 7c,f,i, insets). Thus, all three isoforms
localize similarly in nonpigment cells.We interpret the staining
pattern to represent the accumulation of Pmel17 in intralumenal
vesicles of late endosomes and/or lysosomes, in which Lamp1 accu-
mulates on the limiting membrane (Berson et al, 2001). Given the
correspondence of localization to late endosomes in HeLa cells
and to melanosome precursors in pigment cells, it is likely that
all three isoforms localize similarly in melanocytes as well.
DISCUSSION
In this study, we have identi¢ed a novel splice variant of human
Pmel17/gp100, an important constituent of early stage melano-
somes and a common target for tumor-directed T lymphocytes
in melanoma patients. The expression of this variant by normal
and transformed melanocytes has interesting implications for the
function of Pmel17 in melanocytes and for the generation of T
cell epitopes by melanoma cells.
Figure 6. Expression and processing of Pmel17-s in HeLa cells. (a) Immunoprecipitation of three Pmel17 isoforms from metabolically pulse labeled
HeLa cells. MNT-1 cells (lanes 2 and 4) or HeLa cells transiently transfected with expression vectors for Pmel17-l (lane 1), Pmel17-i (lane 3), or Pmel17-s (ls
form; see Fig. 5c lane 5) were labeled for 15 min with 35S-methionine/cysteine. Triton X-100 cell lysates were immunoprecipitated with aPmel-C, fractio-
nated by SDS^PAGE, and analyzed by phosphorimaging. Position of molecular weight markers is indicated to the right, and the positions of the P1 and
band X forms of Pmel17 in MNT-1 cells is indicated to the left. (b) Western blot analysis of Pmel17 isoforms expressed in HeLa cells.Whole cell lysates of
transiently transfected HeLa cells expressing Pmel17-l, Pmel17-i or Pmel17-s were treated or not with EndoH, fractionated by SDS^PAGE on 12% (upper
panel) or 8% (lower panel) polyacrylamide gels, transferred to nitrocellulose using 15% (upper panel) or 2% (lower panel) methanol, and immunoblotted with
antibodies to the cytoplasmic domain (Pmel-C, upper panel) or the lumenal domain (Pmel-N, lower panel). Relevant portions of the gels encompassing the P1,
Mb, and Ma isoforms, and of EndoH-digested P1 (P1’), as indicated, are shown; no other speci¢c bands were reproducibly observed. Variation in band
intensity is due to di¡erent transfection e⁄ciencies, which varied from experiment to experiment.
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Band X represents the novel Pmel17 splice variant, Pmel17-s
In our previous characterization of Pmel17 in human melanocytic
cells (Berson et al, 2001), we showed that a large Ma fragment
is generated as a result of post-Golgi proteolytic processing
of Pmel17. Characterization of Ma, however, was clouded by
the presence of a comigrating band, ‘‘band X’’, that was
immunoprecipitated from metabolically pulse-labeled cells using
anti-Pmel17 antibodies; as Ma and its cognate proteolytic
fragment, Mb, appear only after a chase period, it was di⁄cult
to reconcile the appearance of the Ma-like band X prior to
Golgi processing. We now clearly identify band X as Pmel17-s,
the product of an alternatively spliced Pmel17 mRNA. Because
it lacks part of the central region of the lumenal domain of
Pmel17, Pmel17-s is directly immunoprecipitable with antibodies
to both the N- and C-termini of Pmel17, as well as with
additional antibodies to the lumenal domain (Fig 2). It is
distinguished from Ma based on this immunoreactivity (Ma is
not reactive with antibodies to the C-terminus), on its
appearance in pulse-labeled cells, and on its sensitivity to
EndoH (Figs 1 and 2) (Berson et al, 2001). A band with
similarity to Pmel17-s has been previously observed by other
groups (e.g., see Vogel and Esclamado, 1988; Adema et al, 1996).
Pmel17-s is generated in melanoma cells and in primary
melanocytes (Figs 1 and 4), although the relative proportion of
Pmel17-s among all Pmel17 products varies from cell to cell and
in some cases from experiment to experiment. Although it results
from removal of an exonic sequence present in full-length
Pmel17 mRNA, Pmel17-s is not consistently generated in HeLa
cells transfected with expression vectors for Pmel17-l and
Pmel17-i; this was apparent in an earlier study (Berson et al,
2001) and allowed us to clearly identify Ma in transfected cells.
It does appear to be generated at low levels in Pmel17-l and
Pmel17-i transfected HeLa cells in some experiments (e.g., see
Fig 6a), suggesting that regulation of the alternative splice may
be dependent on cell culture conditions, growth phase of the
cells, or expression level. As the Pmel17-s splice was identi¢ed
both in cDNA that contained and lacked the 21 bp alternative
transcript that distinguishes Pmel17-l from Pmel17-i, the two
alternative splice reactions must be independently regulated.
Thus, human pigment cells can produce at least four distinct
Pmel17 gene products by alternative splicing of a single
precursor mRNA (Fig 5c).
Although mRNA for Pmel17-s was detected by reverse
transcriptase^PCR in all human melanocytic cells tested (Fig 4),
no comparable product was identi¢ed in mouse melanocyte cell
lines. This is consistent with the failure to detect a comparable
product by immunoprecipitation of metabolically pulse-labeled
cells (our unpublished results and Kobayashi et al, 1994).
Interestingly, although the mouse and human products share
considerable homology at both the nucleotide (83%) and amino
acid (75%) level, the region surrounding this alternatively spliced
region varies signi¢cantly in sequence between the two species.
This may explain the absence of the Pmel17-s product in the
mouse. Given that the mouse Pmel17 gene does not encode the
21 bp insertion found in Pmel17-l (Mart|¤ nez-Esparza et al, 1999),
humans have evolved considerable variability in the production
of Pmel17 isoforms relative to mice.
Pmel17-s and the signi¢cance of the repeat region It is
intriguing that Pmel17-s lacks several of the characteristic repeats
Figure 7. Immuno£uorescence microscopy
analyses of the localization of Pmel17-l,
Pmel17-i, and Pmel17-s expressed in HeLa
cells. Transiently transfected HeLa cells expres-
sing Pmel17-l (a^c), Pmel17-i (d^f ), or Pmel17-s
( g^i) were ¢xed and stained with antibodies
HMB50 (IgG2a, to Pmel17) and H4A3 (IgG1,
to Lamp1) and isotype-speci¢c, £uorochrome-
conjugated secondary antibodies (£uorescein
isothiocyanate, anti-g1; Texas Red, anti-g2a).
Cells were analyzed by immuno£uorescence
microscopy (IFM), and stacks of images in mul-
tiple z focal planes were deconvolved using
OpenLab software. Shown are individual ¢elds
for Lamp1 (a,d,g), Pmel17 (b,e,h), and colorized,
merged images (c,f,i). The boxed region in each
panel is magni¢ed 2.5 at the bottom right of
each panel to emphasize the degree of colocali-
zation. Bar: (a) 10 mm.
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present within the lumenal domain of Pmel17-l and Pmel17-i
(Fig 5). This repeat region, ¢rst noted by Kwon et al (1991),
consists of 10 tandem, imperfect repeats of a 13 amino acid
sequence rich in glutamine, threonine, glycine, proline, and
acidic residues. Our data indicate that the reduction in the
number of the repeats has little e¡ect on the post-Golgi
processing or ultimate localization of Pmel17 products expressed
ectopically in HeLa cells (Figs 6 and 7). We speculate that the
repeats may have some other function, such as binding to
melanin intermediates (Donatien and Orlow, 1995; Chakraborty
et al, 1996; Lee et al, 1996), oligomerization, or ¢bril formation
(Berson et al, 2001, 2003). In support of the latter possibility, the
amino acid content of the Pmel17 repeats is similar to that of a
repeat region within a prion-like protein, Sup35p, in the yeast
Saccharomyces cerevisiae; these repeats have been shown to be
required for the ¢bril forming activity of Sup35p (Parham et al,
2001). We are currently assessing the relative ability of Pmel17
isoforms to induce ¢bril formation upon expression in
nonpigment HeLa cells; preliminary results suggest that the
di¡erences are likely to be subtle.
On the other hand, the repeat region of the chicken Pmel17
orthologue, MMP115 (Mochii et al, 1991), di¡ers substantially
in sequence and general amino acid content from that of
mammalian orthologues, perhaps suggesting a role in speci¢c
interactions with distinct melanin intermediates. Interestingly,
whereas there are 10 direct repeats in full-length human Pmel17
and its bovine orthologue, RPE1 (Kim and Wistow, 1992), the
mouse (Kwon et al, 1995; Mart|¤ nez-Esparza et al, 1999) and horse
(Rieder et al, 2000) orthologues, like Pmel17-s, contain only
seven. The di¡erence in repeat number between mouse and
human correlates with a distinction in the ability to detect post-
Golgi processed forms of Pmel17 within melanocytesthese
forms are di⁄cult to detect in the mouse (e.g., see Kobayashi
et al, 1994), yet readily detectable in human melanocytic cells
(this study and Berson et al, 2001). Perhaps the repeats regulate
the kinetics of interactions of Pmel17 with melanins that
ultimately mask Pmel17 antibody epitopes (Donatien and
Orlow, 1995). Nmb (Weterman et al, 1995) and its orthologues
QNR71 (Turque et al, 1996) and osteoactivin (Safadi et al, 2001)
are close homologs of Pmel17 but lack any repeat region;
comparison of the activities of these proteins with those of the
various isoforms of Pmel17 should elucidate a role for the direct
repeats.
Splice variation and anti-melanoma immunity The existence
of a distinct isoform of human Pmel17 has potential relevance
for anti-tumor immunity. Pmel17better known to tumor
immunologists as gp100is a major endogenous and experimental
target for melanoma-reactive T lymphocytes; numerous Pmel17-
derived epitopes have been found to bind to HLA class I and class
II molecules and serve as targets for both CD8þ and CD4þ T
cells, respectively (Kawakami et al, 2000; Overwijk and Restifo,
2000; Slinglu¡ et al, 2000). The most broadly recognized T cell
epitopes cluster either in the amino-terminal region of the
lumenal domain or downstream of the repeat region (Kawakami
et al, 1998b; Castelli et al, 1999; Bullock et al, 2000; Cochlovius et al,
2000; Touloukian et al, 2000; Kierstead et al, 2001; Kobayashi et al,
2001). Nevertheless, the region that is deleted from Pmel17-s spans
two consensus binding epitopes for HLA-DR molecules, including
one with very high a⁄nity for both HLA-DRB10404 and
DRB10401 (Kierstead et al, 2001), and another with broad HLA-
DR binding activity (Cochlovius et al, 2000).The latter epitope was
capable of eliciting a T cell proliferative response from several
healthy donors (Cochlovius et al, 2000). Thus, altered expression of
Pmel17 isoforms may a¡ect T cell immune responses. Furthermore,
the novel peptide sequence generated by Pmel17-s could potentially
encompass a neorecognition element for certain HLA-DR
molecules. That such a neoepitope could exist is underscored by
the ¢nding that tumor-in¢ltrating CD8þ T cells derived from a
melanoma patient recognized an HLA-A24-binding peptide
derived from an intronic sequence (Robbins et al, 1997). The
existence of such an epitope from Pmel17-s could potentially
explain the reactivity of Pmel17-speci¢c tumor-in¢ltrating T cells
from a melanoma patient that were unable to recognize
autologous antigen-presenting cells pulsed with peptides derived
from the entire sequence of Pmel17-l and Pmel17-i (Robbins et al,
2002).
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